PDF herunterladen
Aktuelle Rheumatologie 2016; 41(02): 132-136
DOI: 10.1055/s-0042-104112
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Autoimmunphänomene bei hämatologischen Systemerkrankungen

Autoimmunity in Haematological Malignancies
A. H. Hautmann
1   Klinik und Poliklinik für Innere Medizin III, Uniklinik Regensburg, Regensburg, Deutschland
,
W. Herr
1   Klinik und Poliklinik für Innere Medizin III, Uniklinik Regensburg, Regensburg, Deutschland
,
E. Holler
1   Klinik und Poliklinik für Innere Medizin III, Uniklinik Regensburg, Regensburg, Deutschland
,
M. Fleck
2   Asklepios Klinikum, Klinik und Poliklinik für Rheumatologie/Klinische Immunologie, Bad Abbach, Deutschland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. April 2016 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Autoimmunphänomene bei hämatologischen malignen Grunderkrankungen zeigen ein komplexes klinisches Erscheinungsbild und können zunächst zu der Diagnose einer Autoimmunerkrankung führen, ohne dass die hämatologische Diagnose gestellt wird. Dies kann zu einer Therapieverzögerung der hämatologischen Neoplasie führen, was die Prognose des Patienten potentiell verschlechtern kann. Deshalb ist es essentiell, bei bestimmten klinischen Merkmalen und laborchemischen Konstellationen eine zugrunde liegende hämatologische Erkrankung auszuschließen. Häufige hämatologische Neoplasien als Ursache für Autoimmunphänomene sind Lymphome (Non-Hodgkin-Lymphome, Hodgkin-Lymphome) und myelodysplastische sowie myeloproliferative Erkrankungen.

Abstract

Paraneoplastic rheumatological syndromes in association with haematological malignancies present in a complex clinical setting and may mislead to the diagnosis of an autoimmune disorder. It is of the utmost importance to discover the underlying haematological malignancy. Otherwise a delay in diagnosis might impair treatment options and the prognosis of the patient. Poor response to therapies used in non-paraneoplastic rheumatic conditions and/or characteristic clinical signs should trigger the rheumatologist to exclude an underlying malignancy. Frequent haematological malignancies as a cause of an autoimmune disorder are lymphomas (Non-Hodgkin lymphoma, Hodgkin lymphoma) and myelodysplastic or myeloproliferative disorders.

Schlüsselwörter

paraneoplastische Autoimmunphänomene - paraneoplastische rheumatologische Erkrankungen - hämatologische Neoplasien und Autoimmunphänomene

Key words

paraneoplastic autoimmune disorders - paraneoplastic rheumatological syndromes - haematological malignancies and autoimmunity
 

  • Literatur

  • 1 Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol 2013; 25: 44-49
    CrossrefPubMedGoogle Scholar
  • 2 Alias A, Rodriguez EJ, Bateman HE et al. Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy. Bull NYU Hosp Jt Dis 2012; 70: 109-114
    PubMedGoogle Scholar
  • 3 Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol 2014; 10: 662-670
    CrossrefPubMedGoogle Scholar
  • 4 Morel J, Deschamps V, Toussirot E et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 2008; 67: 244-247
    CrossrefPubMedGoogle Scholar
  • 5 Kisacik B, Onat AM, Kasifoglu T et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis 2014; 17: 640-645
    CrossrefPubMedGoogle Scholar
  • 6 Zupancic M, Annamalai A, Brenneman J et al. Migratory polyarthritis as a paraneoplastic syndrome. J Gen Intern Med 2008; 23: 2136-2139
    CrossrefPubMedGoogle Scholar
  • 7 Brickmann K, Brezinschek RI, Yazdani-Biuki B et al. Superior specificity of anti-citrullinated peptide antibodies in patients with chronic lymphocytic leukemia and arthritis. Clin Exp Rheumatol 2010; 28: 888-891
    PubMedGoogle Scholar
  • 8 Larson E, Etwaru D, Siva C et al. Report of anti-CCP antibody positive paraneoplastic polyarthritis and review of the literature. Rheumatol Int 2011; 31: 1635-1638
    CrossrefPubMedGoogle Scholar
  • 9 Fam AG. Paraneoplastic rheumatic syndromes. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 515-533
    CrossrefPubMedGoogle Scholar
  • 10 Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin. Arthritis Rheum 2010; 40: 89-94
    CrossrefPubMedGoogle Scholar
  • 11 Paira S, Graf C, Roverano S et al. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol 2002; 21: 146-149
    CrossrefPubMedGoogle Scholar
  • 12 Origuchi T, Arima K, Kawashiri S et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol 2012; 22: 584-588
    CrossrefPubMedGoogle Scholar
  • 13 Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-117
    CrossrefPubMedGoogle Scholar
  • 14 Myklebust G, Wilsgaard T, Jacobsen BK et al. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 2002; 29: 2143-2147
    PubMedGoogle Scholar
  • 15 Racanelli V, Prete M, Minoia C et al. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008; 7: 352-358
    CrossrefPubMedGoogle Scholar
  • 16 Naschitz JE, Slobodin G, Yeshurun D et al. Atypical polymyalgia rheumatica as a presentation of metastatic cancer. Arch Intern Med 1997; 157: 2381
    PubMedGoogle Scholar
  • 17 Suzuki S, Ikusaka M, Miyahara M et al. Positron emission tomography findings in a patient with multiple myeloma of polymyalgia rheumatica-like symptoms caused by paraneoplastic syndrome. BMJ Case Rep 2014; DOI: 10.1136/bcr-2013-203326.
    PubMedGoogle Scholar
  • 18 Fautrel B, Fermand J, Sibilia J et al. Amyloid arthropathy in the course of multiple myeloma. J Rheumatol 2002; 29: 1473-1481
    PubMedGoogle Scholar
  • 19 Prokaeva T, Spencer B, Kaut M et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007; 56: 3858-3868
    CrossrefPubMedGoogle Scholar
  • 20 Manger B Schett Palmar fasciitis and polyarthritis syndrome-systematic literature review of 100 cases. Semin Arthritis Rheum 2014; 44: 105-111
    CrossrefPubMedGoogle Scholar
  • 21 András C, Csiki Z, Ponyi A et al. Paraneoplastic rheumatic syndromes. Rheumatol Int 2006; 26: 376-382
    CrossrefPubMedGoogle Scholar
  • 22 El-Haddad B, Hammoud D, Shaver T et al. Malignancy-associated multicentric reticulohistiocytosis. Rheumatol Int 2011; 31: 1235-1238
    CrossrefPubMedGoogle Scholar
  • 23 Snow JL, Muller SA. Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study. Br J Dermatol 1995; 133: 71-76
    PubMedGoogle Scholar
  • 24 Ito T, Goto K, Yoh K et al. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. J Thorac Oncol 2010; 5: 976-980
    CrossrefPubMedGoogle Scholar
  • 25 Hautmann AH, Hautmann MG, Kölbl O et al. Tumor-Induced Osteomalacia: an Up-to-Date Review. Curr Rheumatol Rep 2015; 17: 512
    PubMedGoogle Scholar
  • 26 Hautmann AH, Schroeder J, Wild P et al. Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin. Case Rep Endocrinol 2014; 729387
    PubMedGoogle Scholar
  • 27 Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab 2012; 97: 2947-2956
    CrossrefPubMedGoogle Scholar
  • 28 Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100
    CrossrefPubMedGoogle Scholar
  • 29 Limaye VS, Lester S, Bardy P et al. A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 2012; 32: 611-619
    CrossrefPubMedGoogle Scholar
  • 30 Fardet L, Dupuy A, Gain M et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88: 91-97
    CrossrefPubMedGoogle Scholar
  • 31 Chinoy H, Fertig N, Oddis CV et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66: 1345-1349
    CrossrefPubMedGoogle Scholar
  • 32 Casciola-Rosen L, Nagaraju K, Plotz P et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601
    CrossrefPubMedGoogle Scholar
  • 33 Hengstman GJD, Vree Egberts WTM, Seelig HP et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65: 242-245
    CrossrefPubMedGoogle Scholar
  • 34 Fain O, Hamidou M, Cacoub P et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57: 1473-1480
    CrossrefPubMedGoogle Scholar
  • 35 Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 2008; 35: 294-304
    PubMedGoogle Scholar
  • 36 Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 1995; 25: 134-142
    CrossrefPubMedGoogle Scholar
  • 37 Francès C, el Rassi R, Laporte JL et al. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 2001; 80: 173-179
    CrossrefPubMedGoogle Scholar
  • 38 Yanagi T, Matsumura T, Kamekura R et al. Relapsing polychondritis and malignant lymphoma: is polychondritis paraneoplastic?. Arch Dermatol 2007; 143: 89-90
    PubMedGoogle Scholar
  • 39 Buggiani G, Krysenka A, Grazzini M et al. Paraneoplastic vasculitis and paraneoplastic vascular syndromes. Dermatol Ther 2010; 23: 597-605
    CrossrefPubMedGoogle Scholar
  • 40 Kim M, Ye Y, Park H et al. Chemotherapy-related arthropathy. J Rheumatol 2006; 33: 1364-1368
    PubMedGoogle Scholar
  • 41 Hansen SW, Olsen N. Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol 1989; 7: 940-942
    PubMedGoogle Scholar
  • 42 Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431-1442
    CrossrefPubMedGoogle Scholar
  • 43 Tsukadaira A, Okubo Y, Takashi S et al. Repeated arthralgia associated with granulocyte colony stimulating factor administration. Ann Rheum Dis 2002; 61: 849-850
    CrossrefPubMedGoogle Scholar